Journal of International Oncology ›› 2019, Vol. 46 ›› Issue (6): 350-357.doi: 10.3760/cma.j.issn.1673-422X.2019.06.007

Previous Articles     Next Articles

Application of selective CDK4/6 inhibitors in solid cancers therapy

Zhang Baihong1, Yue Hongyun2   

  1. 1Department of Oncology, 940th Hospital of Joint Logistics Support Force of People′s Liberation Army, Lanzhou 730050, China; 2Department of Ophthalmology, 940th Hospital of Joint Logistics Support Force of People′s Liberation Army, Lanzhou 730050, China
  • Online:2019-06-08 Published:2019-07-11
  • Contact: Zhang Baihong, Email: bhzhang1999@126.com E-mail:bhzhang1999@126.com
  • Supported by:

    Natural Science Foundation of Gansu Province of China (1308RJZA181)

Abstract: Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+/HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are  biomarkers, drug resistance and combined therapy in the future.

Key words: Neoplasms, Cyclin-dependent kinases, Therapeutics, Cell cycle